skip to main content
Idioma:
Resultados 1 2 3 next page
Mostrar Somente
Refinado por: Base de dados/Biblioteca: Oxford Journals remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC
Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC
Material Type:
Artigo 		Adicionar ao Meu Espaço

Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC

Mok, T.S.K. ; Lopes, G. ; Cho, B.C. ; Kowalski, D.M. ; Kasahara, K. ; Wu, Y.-L. ; de Castro, G. ; Turna, H.Z. ; Cristescu, R. ; Aurora-Garg, D. ; Loboda, A. ; Lunceford, J. ; Kobie, J. ; Ayers, M. ; Pietanza, M.C. ; Piperdi, B. ; Herbst, R.S.

Annals of oncology, 2023-04, Vol.34 (4), p.377-388 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
2
Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma
Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma

Shitara, K. ; Özgüroğlu, M. ; Bang, Y.-J. ; Di Bartolomeo, M. ; Mandalà, M. ; Ryu, M.-H. ; Caglevic, C. ; Chung, H.C. ; Muro, K. ; Van Cutsem, E. ; Kobie, J. ; Cristescu, R. ; Aurora-Garg, D. ; Lu, J. ; Shih, C.-S. ; Adelberg, D. ; Cao, Z.A. ; Fuchs, C.S.

Annals of oncology, 2021-09, Vol.32 (9), p.1127-1136 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
3
Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab
Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab
Material Type:
Artigo 		Adicionar ao Meu Espaço

Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab

Fabrizio, D. ; Cristescu, R. ; Albacker, L. ; Snyder, A. ; Ward, A. ; Lunceford, J. ; Aurora-Garg, D. ; Jin, F. ; Hopkins, J. ; Rubin, E. ; Hegde, P.

Annals of oncology, 2021-09, Vol.32 (9), p.1193-1194 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
4
Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407
Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407

Paz-Ares, L. ; Langer, C.J. ; Novello, S. ; Halmos, B. ; Cheng, Y. ; Gadgeel, S.M. ; Hui, R. ; Sugawara, S. ; Borghaei, H. ; Cristescu, R. ; Aurora-Garg, D. ; Albright, A. ; Loboda, A. ; Kobie, J. ; Lunceford, J. ; Ayers, M. ; Lubiniecki, G.M. ; Pietanza, M.C. ; Piperdi, B. ; Garassino, M.C.

Annals of oncology, 2019-10, Vol.30, p.v917-v918 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
5
Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study
Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study

Ledermann, J.A. ; Shapira-Frommer, R. ; Santin, A. ; Lisyanskaya, A.S. ; Pignata, S. ; Vergote, I. ; Raspagliesi, F. ; Sonke, G.S. ; Birrer, M.J. ; Provencher, D.M. ; Sehouli, J. ; Colombo, N. ; González-Martín, A. ; Oaknin, A. ; Ottevanger, P.B. ; Rudaitis, V. ; Cristescu, R. ; Kobie, J. ; Ruman, J. ; Matulonis, U.A.

Annals of oncology, 2018-10, Vol.29, p.viii728-viii728 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
6
A novel framework for evaluating biomarker response relationships in immuno-oncology (IO)
A novel framework for evaluating biomarker response relationships in immuno-oncology (IO)
Material Type:
Artigo 		Adicionar ao Meu Espaço

A novel framework for evaluating biomarker response relationships in immuno-oncology (IO)

Evelhoch, J.L. ; Mogg, R. ; Cristescu, R. ; Aurora-Garg, D. ; Chow, L.Q. ; Loi, S. ; Catenacci, D.V.T. ; Matulonis, U.A. ; Ott, P.A. ; Antonarakis, E.S. ; Poehlein, C.H. ; Joe, A. ; Keefe, S.M. ; Kang, P. ; Karantza, V. ; Cheng, J. ; Rubin, E.H.

Annals of oncology, 2018-10, Vol.29, p.viii31-viii31 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
7
789P PD-L1 and tumor mutational burden (TMB) in standard-of-care (SOC): Treated advanced cervical cancer
789P PD-L1 and tumor mutational burden (TMB) in standard-of-care (SOC): Treated advanced cervical cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

789P PD-L1 and tumor mutational burden (TMB) in standard-of-care (SOC): Treated advanced cervical cancer

Baek, M-H. ; Chen, L. ; Jelinic, P. ; Cristescu, R. ; Jin, X.Y. ; Shao, C. ; Tekin, C. ; Park, J-Y.

Annals of oncology, 2021-09, Vol.32, p.S758-S758 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
8
1048P Baseline and post-treatment biomarkers of resistance to anti-PD-1 (aPD1) therapy in acral and mucosal melanoma
1048P Baseline and post-treatment biomarkers of resistance to anti-PD-1 (aPD1) therapy in acral and mucosal melanoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

1048P Baseline and post-treatment biomarkers of resistance to anti-PD-1 (aPD1) therapy in acral and mucosal melanoma

Lee, J. ; Liu, X.Q. ; Zhao, Q. ; Kim, K-M. ; Kim, S.T. ; Sun, Y. ; Yearley, J. ; Choudhury, T. ; Webber, A. ; Krepler, C. ; Cristescu, R. ; Shui, I.

Annals of oncology, 2021-09, Vol.32, p.S877-S877 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
9
796P Association between biomarkers and clinical outcomes of lenvatinib (L) + pembrolizumab (P) in advanced endometrial cancer (EC): Results from KEYNOTE-146/study 111
796P Association between biomarkers and clinical outcomes of lenvatinib (L) + pembrolizumab (P) in advanced endometrial cancer (EC): Results from KEYNOTE-146/study 111
Material Type:
Artigo 		Adicionar ao Meu Espaço

796P Association between biomarkers and clinical outcomes of lenvatinib (L) + pembrolizumab (P) in advanced endometrial cancer (EC): Results from KEYNOTE-146/study 111

Makker, V. ; Taylor, M.H. ; Aghajanian, C. ; Cohn, A.L. ; Brose, M.S. ; DiSimone, C. ; Cao, A. ; Suttner, L. ; Loboda, A. ; Cristescu, R. ; Jelinic, P. ; Snyder, A. ; Nebozhyn, M. ; Lunceford, J. ; Orlowski, R. ; Dutta, L. ; Matsui, J. ; Dutcus, C. ; Minoshima, Y. ; Messing, M.

Annals of oncology, 2021-09, Vol.32, p.S760-S760 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
10
1416P Genomic landscape of late-stage gastric cancer
1416P Genomic landscape of late-stage gastric cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

1416P Genomic landscape of late-stage gastric cancer

Janjigian, Y.Y. ; Cecchini, M. ; Shitara, K. ; Enzinger, P.C. ; Wainberg, Z.A. ; Catenacci, D.V. ; Chau, I. ; Satoh, T. ; Lee, J. ; Loboda, A. ; Kobie, J. ; Li, Y. ; Shih, C-S. ; Cristescu, R. ; Cao, Z.A.

Annals of oncology, 2021-09, Vol.32, p.S1062-S1063 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
Resultados 1 2 3 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (29)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (29)
  2. Outros  (1)
  3. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de2011  (2)
  2. 2011Até2015  (2)
  3. 2016Até2018  (7)
  4. 2019Até2021  (19)
  5. Após 2021  (1)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.